Navigation Links
A Newly Identified Immunosuppressive Protein in Rheumatoid Arthritis

A complex autoimmune disease, rheumatoid arthritis (RA) is characterized by chronic inflammation and progressive joint damage. This process begins with hyperplasia//, or excessive increase in size and thickness, of synovial tissue. Along with provoking cartilage and bone destruction, this abnormal tissue growth is resistant to apoptosis, the natural cell death vital to the generation of healthy new cells.

Decoy receptor 3 (DcR3) is a newly identified member of the tumor necrosis factor receptor (TNFR) superfamily. A soluble protein, it is overexpressed in tumor cells, including lung and colon cancers, gastrointestinal tract tumors, and leukemia. It is also expressed in a variety of normal tissue—the colon, lung, stomach, spleen, lymph node, pancreas, and spinal cord. Because rheumatoid synovial cells share traits with tumor cells—both are resistant to apoptosis, both proliferate aggressively— DcR3 might play a role in the destructive course of RA. To investigate this possibility, researchers at Kobe University School of Medicine in Japan conducted the first study of DcR3 expression in RA fibroblast-like synoviocytes (FSL)—cells in the synovial membrane instrumental to the production of cartilage as well as synovial fluid. Featured in the April 2007 issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis), their findings expose DcR3 as one of the factors culpable for RA's hallmark hyperplasia and its crippling consequences.

For their novel study of DcR3, the researchers isolated and cultured FLS from 19 patients with RA, obtained during total knee replacement surgery. For comparison, FLS was also extracted in a similar manner from 14 patients with osteoarthritis (OA). For all samples, expression of DcR3 in FLS was measured by reverse-transcriptase-polymerase chain reaction and Western blotting. Then, apoptosis was induced by Fas, a protein ligand and member of the tumor necrosis factor (TNF) family. Finally, FLS we re incubated with the proinflammatory TNFá prior to Fas-induced apoptosis, and apoptosis was measured.

DcR3 was expressed in both the RA and OA FLS, with no significant quantitative differences found between the samples. However, TNFá increased DcR3 expression in and inhibited Fas-induced apoptosis in RA FLS, but not in OA FLS.

This study affirms DcR3 as an immunosuppressive agent that actually protects destructive rheumatoid synovial cells against death. "We suggest that DcR3 expressed in RA FLS is increased by TNFá, making it one of the pathologic factors that induces hyperplasia of rheumatoid synovium," states researcher and author, Dr. Yasushi Miura. "Thus, strategies aimed at down-regulation of DcR3 in FLS warrant further investigation as a possible therapeutic approach in RA."

Even in this era of TNF-alpha inhibitors and other powerful drugs, there are constantly new aspects of biology being found that offer different forms of treatments for rheumatoid arthritis.

Source-Eurekalert'"/>




Related medicine news :

1. Obesity The Major Cause Of The Increase In Newly Diagnosed Diabetes
2. Newly Identified Strains Of Chlamydia Trachomatis – A Gateway To New Disease
3. Newly Cloned Wheat Gene May Boosts Foods Nutrient Contents – Says A Researc
4. Newly Discovered Immune Defense May Be Impaired In CF Airways
5. Differences Between BP Medicines and Newly-Diagnosed Diabetes Identified
6. Moratorium Proposed on Advertisements of Newly Approved Drugs
7. Potential New Cancer Gene Identified
8. Alcohol Dependence Gene Identified
9. More Causes of Bladder Cancer Identified
10. Dyslexia Gene Identified and Called "KIAA0319"
11. New Enzyme Identified For Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... Los Angeles, California (PRWEB) , ... January 19, ... ... at the hands of a doctor who administered fillers that resulted in severe ... her unprecedented case was taken on by doctors at UCLA Medical Center, who ...
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... ... Tranquility acoustic and privacy panel system. , The Tranquility privacy panel system ... a collaborative office environment. Tranquility panels help reduce noise and provide the visual ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sam & Associates Insurance Agency, a full service ... in the California Bay Area, is launching a charity drive to raise awareness of ... disease is the primary killer of adult men and women in America, and is ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the third ... New Jersey and the surrounding area, is inaugurating a charity event to ... commonly known as Lou Gehrig's disease or motor neurone disease, is a deadly ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... the 2017 Spring Create Real Impact contest from Impact Teen Drivers and California ... http://www.createrealimpact.com . , Educational grants totaling $15,000 will be awarded for ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... LONDON , Jan. 18, 2017 ... 2022 Summary GlobalData,s new report, "South Korea ... data on the South Korea Insulin Delivery market. The ... (in units) and average prices (USD) within market segments ... Insulin Pump Accessories. The report also provides company ...
(Date:1/18/2017)... PUNE, India , January 18, 2017 ... "Breast Imaging Technologies Market by Type: Global Opportunity Analysis and ... market size was valued at $2,544 million in 2015 and ... a CAGR of 8.4% from 2016 to 2022. ... together accounted for over three-fourths market share in 2015. Ionizing ...
(Date:1/18/2017)... Calif. , Jan. 18, 2017  Adaptive Sound Technologies, ... today a new partnership with Hyatt Place Nashville/Downtown to ... providing ASTI LectroFan sleep therapy machines in over two ... of the most important parts of having a great ... general manager of Hyatt Place Nashville/Downtown. "We,re pleased to ...
Breaking Medicine Technology: